5F-CUMIL-P7아이카

5F-CUMYL-P7
5F-CUMIL-P7아이카
5F-CUMYL-P7AICA Structure.svg
법적현황
법적현황
식별자
  • 1-(5-Fluoropentyl)-N-(2-페닐프로판-2-yl)피롤로[2,3-b]피리딘-3-카박스아미드
CAS 번호
  • 2171492-36-5
펍켐 CID
켐스파이더
유니
화학 및 물리적 데이터
공식C22H26FN3O
어금질량367.468 g·1998−1
3D 모델(JSmol)
  • FCCCCn1cc(c3cccnc13)C(=O)NC(C)c2ccc2
  • InChI=1S/C22H26FN3O/c1-22(2,17-10-5-3-6-11-17)25-21(27)19-16-26(15-8-4-7-13-23)20-18(19)12-9-14-24-20/h3,5-6,9-12,14,16H,4,7-8,13,15H2,1-2H3,(H,25,27)
  • 키:MXJYOUMYJGNQEY-UHFFFAOYSA-N

5F-CUMIL-P7AICA(CUMIL-5F-P7이라고도 함)AICA 또는 SGT-263)는 피롤로[2,3-b]피리딘-3-카복사미드 기반 합성 카나비노이드로, 디자이너 약품으로 판매되어 왔다.[1][2][3][4][5][6] 2015년 2월 EMCDDA에 의해 처음 확인되었다.[7]

참고 항목

참조

  1. ^ Ernst L, Brandhorst K, Papke U, Altrogge A, Zodel S, Langer N, Beuerle T (August 2017). "Identification and quantification of synthetic cannabinoids in 'spice-like' herbal mixtures: Update of the German situation in early 2017". Forensic Science International. 277: 51–58. doi:10.1016/j.forsciint.2017.05.019. PMID 28601726.
  2. ^ Staeheli SN, Poetzsch M, Veloso VP, Bovens M, Bissig C, Steuer AE, Kraemer T (January 2018). "In vitro metabolism of the synthetic cannabinoids CUMYL-PINACA, 5F-CUMYL-PINACA, CUMYL-4CN-BINACA, 5F-CUMYL-P7AICA and CUMYL-4CN-B7AICA". Drug Testing and Analysis. 10 (1): 148–157. doi:10.1002/dta.2298. PMID 28885775.
  3. ^ Bovens M, Bissig C, Staeheli SN, Poetzsch M, Pfeiffer B, Kraemer T (December 2017). "Structural characterization of the new synthetic cannabinoids CUMYL-PINACA, 5F-CUMYL-PINACA, CUMYL-4CN-BINACA, 5F-CUMYL-P7AICA and CUMYL-4CN-B7AICA". Forensic Science International. 281: 98–105. doi:10.1016/j.forsciint.2017.10.020. PMID 29125990.
  4. ^ Banister SD, Adams A, Kevin RC, Macdonald C, Glass M, Boyd R, Connor M, McGregor IS, Havel CM, Bright SJ, Ventura Vilamala M, Gil Lladanosa C, Barratt MJ, Gerona RR (August 2018). "Synthesis and pharmacology of new psychoactive substance 5F‐CUMYL‐P7AICA, a scaffold‐hopping analog of synthetic cannabinoid receptor agonists 5F‐CUMYL‐PICA and 5F‐CUMYL‐PINACA". Drug Testing and Analysis. 11 (2): 279–291. doi:10.1002/dta.2491. PMID 30151911.
  5. ^ Walle N, Nordmeier F, Doerr AA, Peters B, Laschke MW, Menger MD, Schmidt PH, Meyer MR, Schaefer N (July 2020). "Comparison of in vitro and in vivo models for the elucidation of metabolic patterns of 7-azaindole-derived synthetic cannabinoids exemplified using cumyl-5F-P7AICA". Drug Testing and Analysis. 13 (1): 74–90. doi:10.1002/dta.2899. PMID 32678962.
  6. ^ Gatch MB, Tourigny A, Shetty RA, Forster MJ (February 2021). "Behavioral pharmacology of five novel synthetic cannabinoids". Behavioural Pharmacology. doi:10.1097/FBP.0000000000000618. PMC 8364570. PMID 33595956.
  7. ^ "Annual Report on the implementation of Council Decision 2005/387/JHA" (PDF). Europol. 2015.
  8. ^ a b c Cannaert A, Sparkes E, Pike E, Luo JL, Fang A, Kevin RC, Ellison R, Gerona R, Banister SD, Stove CP (2020). "Synthesis and in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA". ACS Chemical Neuroscience. 11 (24): 4434–4446. doi:10.1021/acschemneuro.0c00644. PMID 33253529. S2CID 227246346.